Table 2.
Pretreatment characteristics of eligible patients
| WPRT (n = 807) |
PORT (n = 110) |
Total (n = 917) |
|
|---|---|---|---|
| Age (y) | |||
| Median | 71 | 70 | 71 |
| Range | 47-84 | 51-88 | 47-88 |
| Q1-Q3 | 66-75 | 67-73 | 66-74 |
| Karnofsky performance status | |||
| 70-80 | 56 (6.9%) | 9 (8.2%) | 65 (7.1%) |
| 90-100 | 751 (93.1%) | 101 (91.8%) | 852 (92.9%) |
| Tumor stage | |||
| T1 | 383 (47.5%) | 52 (47.3%) | 435 (47.4%) |
| T2 | 424 (52.5%) | 58 (52.7%) | 482 (52.6%) |
| Node stage | |||
| N0 | 16 (2.0%) | 16 (14.5%) | 32 (3.5%) |
| NX | 791 (98.0%) | 94 (85.5%) | 885 (96.5%) |
| Differentiation | |||
| Well | 96 (11.9%) | 44 (40.0%) | 140 (15.3%) |
| Moderately | 516 (63.9%) | 61 (55.5%) | 577 (62.9%) |
| Poor/undifferentiated | 195 (24.2%) | 5 (4.5%) | 200 (21.8%) |
| Prostate-specific antigen levels | |||
| <4 | 75 (9.3%) | 14 (12.7%) | 89 (9.7%) |
| 4-20 | 732 (90.7%) | 96 (87.3%) | 828 (90.3%) |
| Intercurrent disease | |||
| Absent | 220 (27.3%) | 32 (29.1%) | 252 (27.5%) |
| Present | 585 (72.5%) | 77 (70.0%) | 662 (72.2%) |
| Unknown | 2 (0.2%) | 1 (0.9%) | 3 (0.3%) |
| Gleason score | |||
| 2-6 | 448 (55.5%) | 103 (93.6%) | 551 (60.1%) |
| 7 | 257 (31.8%) | 4 (3.6%) | 261 (28.5%) |
| 8-10 | 77 (9.5%) | 2 (1.8%) | 79 (8.6%) |
| Unknown | 25 (3.1%) | 1 (0.9%) | 26 (2.8%) |
| Testosterone level (ng/dL) | |||
| Median | 370.00 | 352.29 | 367.00 |
| Range | 42.00-1380.40 | 76.00-800.00 | 42.00-1380.40 |
| Q1-Q3 | 280.00-475.00 | 274.00-454.00 | 279.00-466.00 |
PORT, prostate-only radiation therapy; Q1, first quartile; Q3, third quartile; WPRT, whole pelvis radiation therapy.